https://www.prnewswire.com/news-releases/aspyrian-therapeutics-inc-closes-425m-series-a-extension-financing-to-support-the-execution-of-phase-1-clinical-studies-of-the-precision-targeted-cancer-therapy-rm-1929-to-treat-late-stage-recurrent-head-and-neck-cancers-300119243.html
Aspyrian Therapeutics Inc. Closes $4.25M Series A Extension Financing to Support the Execution of...
/PRNewswire/ -- Aspyrian Therapeutics Inc., a clinical stage drug development company creating precision-targeted therapies to treat cancer based on its...